Pharmaco-Economic Consequences of Losartan Therapy in Patients Undergoing Diabetic End Stage Renal Disease in EU and USA

Author： de Portu Simona Citarella Anna Cammarota Simona Menditto Enrica Mantovani Lorenzo G.

Publisher： Informa Healthcare

ISSN： 1064-1963

Source： Clinical and Experimental Hypertension, Vol.33, Iss.3, 2011-05, pp. : 174-178

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Modified end-stage renal disease risk score for Chinese type 2 diabetic patients—the Hong Kong Diabetes Registry

By Yang X. So W. Kong A. Ho C. Lam C. Ng M. Lyu R. Yin D. Chow C. Cockram C. Tong P. Chan J.

Diabetologia, Vol. 50, Iss. 6, 2007-06 ,pp. : 1348-1350

Springer Publishing Company

Access to resources Recommend Favorite

Calciphylaxis in end-stage renal disease patients

By Verdalles Ursula García de Vinuesa Soledad Luño José

Nephrology Dialysis Transplantation, Vol. 27, Iss. 9, 2012-09 ,pp. : 3663-3663

Oxford University Press

Access to resources Recommend Favorite

Aspirin, beta-blocker and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction

By Berger A.K. Duval S. Krumholz H.M.

ACC Current Journal Review, Vol. 12, Iss. 5, 2003-09 ,pp. : 17-17

Elsevier

Access to resources Recommend Favorite

Improved survival rate in patients with diabetes and end-stage renal disease in Denmark

By Sørensen V. Mathiesen E. Heaf J. Feldt-Rasmussen B.

Diabetologia, Vol. 50, Iss. 5, 2007-05 ,pp. : 922-929

Springer Publishing Company

Access to resources Recommend Favorite

The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease

By Mohideen Pharis Bornemann Michael Sugihara Jared Genadio Viola Sugihara Valerie Arakaki Richard

Endocrine Journal, Vol. 28, Iss. 2, 2005-11 ,pp. : 181-186

Humana Press, Inc

Access to resources Recommend Favorite